Crossmark Global Holdings’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.6M Buy
129,445
+49,645
+62% +$10.7M 0.42% 46
2026
Q1
$17.4M Buy
79,800
+16,686
+26% +$3.7M 0.26% 90
2025
Q4
$14.4M Sell
63,114
-1,818
-3% -$414K 0.21% 111
2025
Q3
$15M Buy
64,932
+19,340
+42% +$3.94M 0.23% 106
2025
Q2
$8.46M Sell
45,592
-717
-2% -$133K 0.14% 182
2025
Q1
$9.7M Sell
46,309
-31,083
-40% -$6.04M 0.17% 148
2024
Q4
$13.8M Sell
77,392
-3,435
-4% -$632K 0.25% 92
2024
Q3
$16M Buy
80,827
+1,045
+1% +$195K 0.28% 85
2024
Q2
$13.7M Sell
79,782
-4,199
-5% -$696K 0.26% 88
2024
Q1
$15.3M Sell
83,981
-11,161
-12% -$1.92M 0.29% 78
2023
Q4
$14.7M Buy
95,142
+1,738
+2% +$253K 0.31% 75
2023
Q3
$13.9M Buy
93,404
+588
+0.6% +$86.3K 0.32% 74
2023
Q2
$14M Buy
92,816
+3,934
+4% +$577K 0.3% 77
2023
Q1
$14.2M Sell
88,882
-84,689
-49% -$12.9M 0.33% 67
2022
Q4
$28.1M Sell
173,571
-12,693
-7% -$1.95M 0.7% 17
2022
Q3
$25M Buy
186,264
+599
+0.3% +$86K 0.69% 19
2022
Q2
$28.4M Buy
185,665
+61,058
+49% +$9.33M 0.74% 16
2022
Q1
$20.2M Buy
124,607
+481
+0.4% +$69.9K 0.45% 39
2021
Q4
$16.8M Buy
124,126
+8,656
+7% +$1.02M 0.37% 58
2021
Q3
$12.5M Buy
115,470
+1,953
+2% +$223K 0.29% 84
2021
Q2
$12.8M Sell
113,517
-86,390
-43% -$9.73M 0.3% 80
2021
Q1
$21.6M Sell
199,907
-3,432
-2% -$367K 0.54% 31
2020
Q4
$21.8M Sell
203,339
-2,359
-1% -$227K 0.55% 30
2020
Q3
$18M Buy
205,698
+66,801
+48% +$6.29M 0.51% 32
2020
Q2
$13.6M Buy
138,897
+21,747
+19% +$1.91M 0.4% 47
2020
Q1
$8.93M Sell
117,150
-75,438
-39% -$6.43M 0.32% 86
2019
Q4
$17.1M Sell
192,588
-774
-0.4% -$64.3K 0.47% 39
2019
Q3
$14.6M Sell
193,362
-7,089
-4% -$486K 0.43% 50
2019
Q2
$14.6M Sell
200,451
-5,871
-3% -$461K 0.41% 48
2019
Q1
$16.6M Sell
206,322
-1,499
-0.7% -$123K 0.47% 38
2018
Q4
$19.2M Sell
207,821
-5,943
-3% -$523K 0.59% 28
2018
Q3
$20.2M Sell
213,764
-266
-0.1% -$25.2K 0.51% 35
2018
Q2
$19.8M Sell
214,030
-6,299
-3% -$615K 0.53% 27
2018
Q1
$20.9M Sell
220,329
-3,833
-2% -$421K 0.54% 28
2017
Q4
$21.7M Buy
224,162
+11,994
+6% +$1.13M 0.52% 29
2017
Q3
$18.9M Buy
+212,168
New +$16.2M 0.49% 35
2016
Q3
$18.9M Buy
+212,168
New +$13.7M 0.49% 35

Other funds holding ABBV

Crossmark Global Holdings's ABBV Position: Q2 2026 in Review

Crossmark Global Holdings increased its AbbVie (ABBV) stake by 62% in Q2 2026, buying an estimated $10.7M and bringing the position to 129,445 shares worth $32.6M. The position accounts for 0.42% of the portfolio, ranked #46.

Crossmark Global Holdings first reported a position in ABBV in Q3 2016 and has held it in 37 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Crossmark Global Holdings held 129,445 shares of AbbVie worth $32.6M as of Q2 2026.
  • Crossmark Global Holdings bought 49,645 AbbVie shares in Q2 2026, an estimated $10.7M.
  • AbbVie made up 0.42% of Crossmark Global Holdings's portfolio in Q2 2026, its #46 holding.
  • Crossmark Global Holdings first reported a position in AbbVie in Q3 2016 and has held it in 37 quarters since.
  • 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.